Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | PGK1 | P00558 | 1/20 | 0.36 |
| ▸ | PGK2 | P07205 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL915243 | 0.86 | PGK1 (0.37) | KMT2APGK1PGK2RAB9ASMN1; SMN2 | |
| SCHEMBL915165 | 0.86 | ESR1 (0.38) | KMT2APGK1PGK2MEN1LMNA | |
| SCHEMBL4633893 | 0.84 | TRPA1 (0.40) | PGK1PGK2ALDH1A1LMNAENPP2 | |
| SCHEMBL915104 | 0.84 | FDPS (0.40) | PGK1PGK2RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL917066 | 0.84 | HTT (0.37) | KMT2APGK1PGK2POLBCTDSP1 | |
| SCHEMBL1760139 | 0.84 | PGK1 (0.36) | PGK1PGK2SMN1; SMN2CYP3A4CYP2C19 | |
| SCHEMBL1407856 | 0.84 | TRPA1 (0.42) | KMT2APOLBMEN1 | |
| SCHEMBL914038 | 0.83 | ANPEP (0.44) | RAB9AALDH1A1SMN1; SMN2CYP2C19 | |
| SCHEMBL1307263 | 0.82 | PGK1 (0.38) | PGK1PGK2POLBALDH1A1LMNA | |
| SCHEMBL1575114 | 0.82 | SLC6A4 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109705041-B | Triphenylamine substituted-vinyl modified phenanthroimidazole compound, preparation method thereof and application thereof as electroluminescent device | 广东工业大学 | 2022-06-14 | — | — | CN | disclosed |
| EP-1398340-B1 | BLOCK COPOLYMER AND POLYMERIC LUMINESCENT ELEMENT | SUMITOMO CHEMICAL CO (JP) | 2017-11-08 | — | — | EP | disclosed |
| EP-2499121-B1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS. | HOFFMANN LA ROCHE (CH) | 2015-10-07 | — | — | EP | disclosed |
| EP-2635560-B1 | DIHYDROOXAZOL-2-AMINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-09-30 | — | — | EP | disclosed |
| EP-2333006-B1 | Block copolymer and polymeric luminescent element | SUMITOMO CHEMICAL CO (JP) | 2014-10-29 | — | — | EP | disclosed |
| US-8673950-B2 | Dihydrooxazol-2-amine derivatives | HOFFMANN-LAROCHE INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130345241-A1 | DIHYDROOXAZOL-2-AMINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-12-26 | — | — | US | disclosed |
| EP-2635560-A1 | DIHYDROOXAZOL-2-AMINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-11 | — | — | EP | disclosed |
| US-8367869-B2 | Aromatic amine derivative and organic electroluminescence device using the same | IDEMITSU KOSAN CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8354441-B2 | Oxazoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-7125930-B2 | Block copolymer and polymeric luminescent element | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-10-24 | — | — | US | disclosed |
| EP-1408985-A4 | NOVEL PYRIDOPYRIMIDONES AND USES THEREOF | ARIAD PHARMA INC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20040100804-A1 | Solid pahse fluorescence; low molecular weight light emission diodes | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1408985-A1 | NOVEL PYRIDOPYRIMIDONES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2004-04-21 | — | — | EP | disclosed |
| EP-1398340-A1 | BLOCK COPOLYMER AND POLYMERIC LUMINESCENT ELEMENT | Sumitomo Chemical Company, Limited (JP) | 2004-03-17 | — | — | EP | disclosed |
| US-20030100572-A1 | Novel pyridopyrimidones and uses thereof | ARIAD PHARMACEUTICALS,INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2003000270-A1 | NOVEL PYRIDOPYRIMIDONES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| EP-1246829-A1 | NOVEL HETEROCYCLES | ARIAD PHARMACEUTICALS, INC. (US) | 2002-10-09 | — | — | EP | disclosed |
| US-20020103161-A1 | Novel heterocycles | ARIAD PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2001044258-A1 | NOVEL HETEROCYCLES | ARIAD PHARMACEUTICALS, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100572-A1 | Novel pyridopyrimidones and uses thereof | UQCRB, RRM2B, CYP2B6 | FPR2 927/4885KMT2A 3838/4885PGK1 1321/4885 |
| US-20020103161-A1 | Novel heterocycles | BMP2, SOST, BMP4 | FPR2 996/4885KMT2A 3040/4885PGK1 1544/4885 |
| US-20130345241-A1 | DIHYDROOXAZOL-2-AMINE DERIVATIVES | TAAR1, TAAR5, HCRTR1 | FPR2 2493/4885KMT2A 1958/4885PGK1 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.